Incyte Corporation (INCY)
NASDAQ • Healthcare
Last close at October 2, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Incyte Corporation keeps $35 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Oct 27
in 23 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Incyte beat expectations on both the top and bottom line in the second fiscal quarter of 2026, reported July 28, with adjusted EPS of $3.09 topping the $2.15 estimate (+43.7%) and revenue of $1.674 billion topping the $1.504 billion estimate (+11.3%). Revenue rose ~38% to about $1.7 billion from roughly $1.2 billion a year ago, with the United States—by far the largest geography—up ~38% to around $1.6 billion, while Europe increased ~33% to about $105.1 million. Profitability remained elevated, with gross margin near 94% and operating margin around 42%, alongside operating income of roughly $697.9 million. Net income climbed ~45% to about $585.6 million from roughly $405.0 million a year earlier, while adjusted EPS was up ~97% from $1.57. The company generated operating cash flow of about $507.7 million in the quarter. For the next period, consensus calls for EPS of USD -3.31 on revenue of USD 1.472 billion.
Next report — what to expect
Incyte Corporation (INCY) is scheduled to report earnings on October 27, 2026. Wall Street’s next-period consensus calls for EPS of -$3.31 on revenue of $1.47 billion. For trailing context, revenue grew +37.7% year over year last quarter. Incyte has beaten EPS in 5 of its 8 most recent quarters.
About Incyte Corporation
Incyte Corporation develops and markets prescription therapies in biotechnology, with revenue of $5.1 billion in FY2025. Listed on the NASDAQ as INCY, the company combines commercial oncology and hematology drugs with a clinical pipeline and global marketing operations built around therapies it develops itself.
Today's Snapshot
INCY closed 1.6% below yesterday's close, while its sector was flat. Trading was busier than usual, with volume about a quarter more than its usual level.
Trading Volume
Above 10d avg 1.6M
2.1M
vs S&P 500 Today
Underperforming Market
-2.35%
Updated: October 2, 2026 at 20:21 UTC
INCY Headlines
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$109.43 - $122.79Sell
- RSI (14)33.57Neutral
- Stochastic %K (14, 3, 3)7.37Buy
- MACD Level (12, 26)-1.17Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.